Diabetes Care: Obesity with low-titration GD antibodies and type 2 diabetes have good blood sugar control after bariatric surgery

In a recent study published in Diabetes Care, an authoritative journal in the field of diabetes, researchers aimed to assess post-bariatric diabetes relief by assessing the availment of glutamate dextaminase (GAD) antibodies in obese and type 2 diabetes (T2D) patients.
researchers screened 221 patients for type 2 diabetes and obesity who had underwent surgery for obesity.
9 out of 16 GD patients and 112 out of 205 patients without GD underwent surgery.
the effects of diabetes relief and weight loss with the avail or effects of GD.
levels in the GED group were 16-91 IU/mL, and patients with and without GED were similar in age, BMI, diabetes course, insulin, HbA1c, and C peptide treatment ratios (1354±548 vs. 1358±487 pmol/L).
1 year and 5 years after surgery, the BMI reduction was similar to that of diabetes relief in both groups (67% vs. 73%, P.0.71, 56% vs. 57%, P.1.0).
shows that low-titration GD and retention of C peptides in T2D patients should not be a cause for concern for bariatric surgery when the primary purpose is to alleviate diabetes.
。